Laverock Therapeutics raises over £20m in expanded seed round led by Calculus Capital to advance gene control therapies

Laverock Therapeutics is developing programmable gene control technologies that enable advanced therapies to respond dynamically to disease, improving precision, safety and effectiveness in cell-based treatments.